Laboratory efficacy of Bactivec ® and Griselesf ® biolarvicides used for large-scale larviciding in Tanzania

Abstract

From 2022 to 2024, a project piloting large-scale larviciding in Tanzania was implemented in Tanga Region. The project used in-country manufactured biolarvicides, The study was conducted at Ifakara Health Institute (IHI) in Tanzania. Laboratory-based dose–response experiments were performed using Bactivec® and Griselesf® against laboratory-reared early third instar larvae of Anopheles gambiae sensu stricto, Anopheles arabiensis, Anopheles funestus, Aedes aegypti and Culex quinquefasciatus. Larvae were exposed to various concentrations of Bactivec® and Griselesf®. VectoBac® served as a positive control, and distilled water as a negative control. Twelve replicates per concentration, with 25 larvae per replicate, were tested. Larval mortality was recorded at 24 and 48 hours after exposure to Bactivec® and Griselesf®, respectively. Probit regression analysis was used to determine the lethal concentration (LC50 and LC90) values.Bactivec® and Griselesf®. This study independently assessed the efficacy of both biolarvicide products to ensure that they represented a good option for scaling up.

Sustainable Development Goals

SDG - 3: Good Health and Well-being SDG - 9: Industry, Innovation and Infrastructure SDG -13: Climate Action SDG -17: Partnerships for the Goals

Keywords

Citation